Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISRITUX: rituximab discontinuation versus maintenance in ANCA-associated vasculitis remission
NL-OMON61274Phase 4Not yet recruiting
- Sponsor
- Region Östergötland
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by Region Östergötland. Primary endpoint: Disease relapse rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NL-OMON61274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61274.